Healthcare company DexCom, Inc. (NASDAQ: DXCM) reported a double-digit increase in second-quarter earnings and also provided full-year guidance.
- Second-quarter revenue grew 25% year-over-year to $871.3 million, on a reported basis, and 26% on an organic basis
- U.S. revenue rose 21%; international revenue increased 38% on a reported basis and 40% on an organic basis
- Operating income increased sharply to $128.1 million in Q2 from $77.0 million in the prior-year quarter
- Q2 net income was $115.9 million or $0.28 per share, compared to $50.9 million or $0.12 per share in the same quarter of 2022
- As of June 30, Dexcom held $3.64 billion in cash, cash equivalents, and marketable securities
- For fiscal 2023, the management expects total revenue to be in the range of $3.500 billion to 3.550 billion, which represents a 20-22% growth
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
